Health officials in D.C. on alert after person exposes Amtrak rail passengers to measles
March 26 (UPI) -- In Washington, D.C., the Department of Health said Tuesday it is investigating a confirmed measles case.
The infected person took an Amtrak train from New York to the District of Columbia and visited an urgent care facility while contagious, officials said.
"[D.C.] Health was notified of a confirmed case of measles in a person who visited multiple locations in [D.C.] while contagious," health officials said in a statement. '[D.C.] Health is informing people who were at these locations that they may have been exposed."
Amtrak said in a statement, "[D.C.] Public Health has notified Amtrak of a confirmed case of measles in a customer traveling on Amtrak Train 175 from New York to Washington Union Station on Wednesday, March 19. Amtrak is reaching out directly to customers who were on this train to notify them of possible exposure."
The unidentified person was aboard Amtrak's Northeast Regional 175 train southbound March 19 between 7:30 p.m. and 1:30 p.m.
The person was also at the Amtrak Concourse at Union Station, 50 Massachusetts Ave. NE in D.C. from 11:00 p.m. to 1:30 a.m., and at MedStar Urgent Care Adams Morgan between 7:00 p.m. and 11:00 p.m. March 22.
People at those locations during those times who might have been exposed and are not immune are urged to contact their healthcare provider for more guidance.
"Measles is a highly contagious illness that can spread easily through the air when an infected person breathes, coughs, or sneezes," the DC health department said in a statement. "Measles symptoms usually appear in two stages. In the first stage, most people have a fever of greater than 101 degrees, a runny nose, watery red eyes and a cough. These symptoms usually start 7 to 14 days after being exposed."
So far this year, the Centers for Disease Control and Prevention has confirmed 378 measles cases across at least 17 states, as well as in DC.
MedStar Washington Hospital Center infectious diseases director Dr. Glenn Wortmann said in a statement, "It's being spread in communities much more widely than we have seen in the past, and the way to stop that from happening is keep your vaccination rates up."
The Washington Post, citing D.C. chief epidemiologist Brittani Saafir-Callaway, said the contagious person had been vaccinated and was not hospitalized.
Minnesota health officials confirmed Wednesday that the person in question lives in Hennepin County and had recently traveled both domestically and internationally.
People who have gotten two doses of measles vaccine or were born prior to 1957 are immune and no action is recommended for them.
On March 21, the number of measles cases in Texas was greater than the number of measles infections in the entire United States in 2024.
According to the CDC, one person is confirmed to have died from measles in 2025 and a second death is under investigation.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Health Line
6 hours ago
- Health Line
What to Know About Aluminum in Deodorant and Antiperspirant
Unlike antiperspirants, deodorants don't contain aluminum. There's no link between aluminum and cancer or most other health conditions, but those with severe kidney ailments shouldn't use antiperspirants. A lot of people use deodorant or antiperspirant every day. These two products are both effective ways to manage sweating, but they work differently: Deodorants deodorize, or make sweat smell better. Antiperspirants make you sweat, or perspire, less. The article explores the differences between deodorants and antiperspirants and the potential risks of products containing aluminum. Is aluminum in deodorant or antiperspirant? Aluminum isn't found in deodorants. Most antiperspirants, on the other hand, do contain aluminum. Two-in-one products — meaning they're both a deodorant and an antiperspirant — will also include aluminum. Antiperspirants help you sweat less by blocking your pores. Pores are the tiny openings in your skin which sweat comes out of. Antiperspirants contain many ingredients, including aluminum salts. These salts dissolve on your skin and 'melt' into your pores, helping to plug up your pores and stop some of your sweat. Doctors and dermatologists use prescription antiperspirants to help treat health conditions that cause too much sweating, like hyperhidrosis. These antiperspirants can contain 10 to 30% aluminum chlorohydrate, a common type of aluminum salt. This is much higher than the amount of aluminum in over-the-counter (OTC) antiperspirants. Does aluminum stop you from sweating out cancer-causing toxins? Some proponents of aluminum-free products claim that aluminum prevents you from sweating out toxins that could potentially cause cancer. But cancerous toxins aren't removed from the body through the axillary (underarm) lymph nodes. The kidneys and liver help remove these toxins from the body, and they're eventually expelled through the urine and feces. What does the research say about the risks of aluminum? The most common concern about aluminum in antiperspirants and other topical products is that it's linked to breast cancer. However, there's little evidence that typical exposure to aluminum causes cancer or any other health condition. Breast cancer The American Cancer Society notes that there's no scientific evidence that using antiperspirants causes or worsens breast cancer. But some research has suggested that aluminum, at least in large amounts, may be harmful. A study from 2017 asked hundreds of women how often they used antiperspirants and for how long. The group with breast cancer self-reported that they used antiperspirants several times a day, beginning before the age of 30 years. The group of women without breast cancer self-reported that they used antiperspirants less often. Both groups had aluminum salts in their breast tissue. But the women who had breast cancer in the upper outer quadrant and used aluminum products more frequently had higher levels of aluminum in their breast tissue than women without cancer. The researchers were unable to rule out a reverse causation effect. This means it's possible that aluminum simply accumulates in breast tumors and doesn't necessarily cause or increase your risk for breast tumors. A 2018 study suggests that too much aluminum may change how the body makes or responds to the female hormone estrogen. Changes in the endocrine (hormone) system can be harmful to your body over time. On the other hand, other research also shows that the skin absorbs very little (0.01–0.06 percent, according to one literature review) of the aluminum applied to it via products like antiperspirant. More conclusive research into aluminum's effect on cancer is needed. Kidney disease The Food and Drug Administration (FDA) requires manufacturers of antiperspirant products to add a warning to their label that states: 'Ask a doctor before use if you have kidney disease.' This has led some people to believe that the aluminum in these products may also increase the risk of kidney disease. But aluminum in antiperspirant poses no kidney-related risk to the average person. Your kidneys help get rid of aluminum and other waste products in your body. In addition, the National Kidney Foundation (NKF) confirms that it's not possible to absorb enough aluminum through your skin to damage your kidneys. Should you avoid antiperspirants if you have chronic kidney disease (CKD)? The NKF advises people to avoid skin care products with aluminum if they already have stage 4 kidney disease. At this stage, the kidneys are working at a level of only 30% and can't clear out aluminum (also present in kidney medications and dialysis fluid) fast enough. This may allow it to build up in your body and trigger health problems. Bone disease Elevated aluminum levels from chronic dialysis can lead to weakened bones in people with kidney disease, according to a 2018 study. This bone disease is known as osteomalacia. Memory disorders According to a 2016 literature review, chronic exposure to aluminum may increase your risk of developing Alzheimer's disease. A 2018 literature review found that adults with Alzheimer's disease had higher levels of metals like aluminum, mercury, and cadmium in their blood. But these metals were thought to be from their environment. More research is needed to find out whether aluminum or other metals in the body are linked to memory disorders. Do aluminum-free antiperspirants exist? Aluminum-free antiperspirants don't exist, but if you're looking to reduce body odor, you can do so without using an antiperspirant. Deodorants are aluminum-free. Avoid aluminum by trying one of these options: perfume-free or fragrance-free deodorant hypoallergenic deodorant baking soda deodorant, which you can make at home Other products and ingredients to consider include: How to read labels for aluminum The FDA requires manufacturers of antiperspirant products to list aluminum on their product labels. Check deodorant and skin care product labels for aluminum. You may see it under any of these names: aluminum salts aluminum compounds aluminum chlorohydrate aluminum zirconium tetrachlorohydrex gly What happens when you stop using aluminum antiperspirant If you decide to switch from a perspirant that contains aluminum to an aluminum-free deodorant, you may initially experience or notice more sweating. This is because when your sweat glands are no longer blocked by aluminum, more sweat will come out of those glands. An aluminum-free deodorant can minimize underarm odor, and frequent underarm toweling can help soak up sweat. The takeaway Antiperspirants contain aluminum to help you sweat less. Deodorants don't use aluminum as an ingredient. The research is mixed on whether the aluminum from antiperspirants can build up in your body. You're probably more likely to get aluminum from other sources, like medications. That said, there's no scientific evidence that directly links aluminum to cancers or other health conditions. Still, some of this research has led experts to advise that antiperspirant use isn't a good idea for everyone, like people who have severe kidney disease.
UPI
9 hours ago
- UPI
CPAP or Zepbound? Patients, doctors debate sleep apnea treatment
Doctors favor treatment with continuous positive airway pressure, or CPAP, machines, researchers are slated to report this week at a meeting of the American Academy of Sleep Medicine. Adobe stock June 9 (UPI) A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study reports. Doctors favor treatment with continuous positive airway pressure, or CPAP, machines, researchers are slated to report this week at a meeting of the American Academy of Sleep Medicine. The machines keep airways open using mild air pressure provided through a mask patients wear while sleeping. But patients would rather treat their sleep apnea with tirzepatide (Zepbound), a GLP-1 weight-loss drug, researchers found. "The results highlight a need for real-world comparative effectiveness data of CPAP versus tirzepatide, and a potential mismatch between patient and provider preferences when managing comorbid obesity and obstructive sleep apnea," lead researcher Ahmed Khalaf said in a news release. He's a sleep technician in the pulmonary, critical care and sleep medicine division at University of California-San Diego. Nearly 30 million adults in the United States have sleep apnea, a disease in which the upper airway collapses during sleep, causing people to wake repeatedly. CPAP has been considered the gold standard for treating sleep apnea, but some patients find the machines too bulky and noisy. About 50% of people prescribed CPAP either can't use it often enough to matter or find it too bothersome, according to Harvard Medical School. Common problems include mask discomfort, dry mouth, breathing that feels out of sync and noise from the machine. Late last year, the U.S. Food and Drug Administration approved Zepbound as the first drug to treat people with obesity and sleep apnea. At the time, the sleep medicine society hailed the approval as "a positive development for patients and clinicians, who now have another treatment option for this sleep disorder," according to a statement from the academy. But Zepbound is only for people with obesity and sleep apnea, the society noted. Also, Zepbound can reduce the severity of sleep apnea through weight loss, but might not cure the problem. For the new study, researchers analyzed nationwide online survey data from 365 patients, and also spoke to 17 sleep medicine professionals at UCSD. Doctors favored CPAP over Zepbound 53% to 26%, while patients favored Zepbound over CPAP 48% to 35%. Both doctors and patients supported treatment that combined CPAP and Zepbound, but doctors were more enthusiastic about combination therapy, 88% versus 61%. The patients' preferences are likely driven by their own experiences -- 78% said they were either current or former users of CPAP, results show. By comparison, only 23% of patients said they'd ever used Zepbound or Ozempic (semaglutide), the other prominent GLP-1 drug. Principal investigator Dr. Chris Schmickl, an assistant professor of medicine at University of California-San Diego, expressed surprise at the level of disagreement between patients and providers. "Recognizing differing attitudes toward treatment is crucial for developing a realistic and achievable action plan," he said in a news release. "Additional research to understand the underlying reasons behind these preferences will offer valuable insights for providers to guide treatment decisions." Researchers are scheduled to present these findings Wednesday at the society meeting in Seattle. Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal. More information Harvard Medical School has more on managing CPAP problems. Copyright © 2025 HealthDay. All rights reserved.
Yahoo
9 hours ago
- Yahoo
In letter, more than 300 scientists rebuke Trump research cuts, NIH director
June 9 (UPI) -- Hundreds of scientists via the National Institute of Health signed a published letter in protest to NIH leadership and recent cuts by the Trump administration. "We are compelled to speak up when our leadership prioritizes political moment over human safety and faithful stewardship of public resources," more than 300 scientists wrote Monday to NIH Director Jay Bhattacharya in a so-called "Bethesda Declaration" published by Stand Up For Science in rebuke to Trump administration research funding cuts and staff layoffs. They added in the letter to U.S. Health and Human Services Secretary Robert F. Kennedy Jr. and members of Congress overseeing NIH that they "dissent" to Trump's policies that "undermine" the NIH mission, "waste" public resources and harm "the health of Americans and people across the globe." In the open letter, they said the current endeavor to "Make America Healthy Again" referred to "some undefined time in the past." "Keeping NIH at the forefront of biomedical research requires our stalwart commitment to continuous improvement," the letter's writers said, adding that the life-and-death nature of NIH work "demands that changes be thoughtful and vetted." According to the letter, the Trump administration terminated at least 2,100 NIH research grants since January, totaling around $9.5 billion and contracts representing some $2.6 billion in new research. "We urge you as NIH Director to restore grants delayed or terminated for political reasons so that life-saving science can continue," the letter added in part. "This undercuts long-standing NIH policies designed to maximize return on investment by working with grantees to address concerns and complete studies," it said. It further accused the White House of creating a "culture of fear and suppression" among NIH researchers. Bhattacharya, a Stanford University professor and health researcher, called the agency the "crown jewel of American biomedical sciences" and said he had the "utmost respect" for its scientists and mission during his confirmation hearing in March. On Tuesday, Bhattacharya is scheduled to testify before the Senate's Appropriations Committee on Trump's 2026 NIH budget proposal which seeks to cut roughly 40% of NIH's $48 billion budget. "This spending slowdown reflects a failure of your legal duty to use congressionally-appropriated funds for critical NIH research," the scientists penned to Bhattacharya. The letter goes on to characterize it as "dissent" from Trump administration policy, quoting Bhattacharya during his confirmation as saying "dissent is the very essence of science." "Standing up in this way is a risk, but I am much more worried about the risks of not speaking up," says Jenna Norton, a program officer at the NIH's National Institute of Diabetes and Digestive and Kidney Diseases. "If we don't speak up, we allow continued harm to research participants and public health in America and across the globe," Norton said in a statement, adding that if others don't speak up, "we allow our government to curtail free speech, a fundamental American value."
